Among patients with hepatitis C, direct-acting antiviral regimens paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) were shown to be associated with a significant improvement in survival, according to the results of a study published in Clinical Infectious Diseases.
In this case-control study using the Electronically Retrieved Cohort of Hepatitis C Virus Infected Veterans (ERCHIVES), patients with hepatitis C initiated on PrOD (n=1473) or LDV/SOF (n=5497) were matched with control patients who were not started on treatment (n=6970). Exclusion criteria included HIV infection, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing hepatitis C RNA or Fibrosis-4 scores.
Mortality was higher in untreated people (2.5%) compared with those who received PrOD (0.3%; P<.001) or LDV/SOF (1.4%; P <.001). Moreover, survival at 18 months was higher in treated patients compared with those who were untreated.